The Application Value of Spectral CT in the Accurate Staging of Liver Cancer

ConditionLiver Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorYunnan Cancer Hospital

About this trial

Spectral CT was used to prospectively collect medical images and clinical data related to liver cancer, evaluate the effect of image quality in the diagnosis of liver cancer, and evaluate the application value in the accurate staging of liver cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment.

Age > 18 years.

Patients suspected of having liver cancer.

Patients who have signed the informed consent form.

Disqualifiers

Severe cardiac, pulmonary, or renal insufficiency.

Allergy to iodine-based contrast agents.

Inability to cooperate with the CT examination.

Poor image quality of the Quark Spectral CT scan.

Trial design

Design model

Single group

Treatments tested in this trial

  • To explore the value of spectral CT in the diagnosis and treatment of liver cancer

    Diagnostic test

    The CT scan is part of the standard treatment protocol.

Treatment groups

150 Participants
are divided into 1 treatment group
Group A: The application value of spectral CT in the accurate staging of liver cancerExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Pathological TNM staging

Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded

Time frame
1 day

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: